Images List Premium Download Classic

Autoimmune

Autoimmune-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
Novartis Ag
July 12, 2018 - N°20180194839

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17 a. The disclosure more specifically relates to specific antibodies and proteins that are il-17 a antagonists (inhibit the activities of il-17 a and il-17 af) and are capable of inhibiting il-17 a induced cytokine production in in vitro assays, ...
Bicyclic alkyne derivatives and uses thereof
Agency For Science, Technology And Research
July 12, 2018 - N°20180194771

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e....
Pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase
Pharmacyclics Llc
July 12, 2018 - N°20180194762

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treatment of autoimmune and other disease
Cerulean Pharma Inc.
July 12, 2018 - N°20180193486

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Methods of treating cancer, infectious disease, and autoimmune disease using cxc chemokines
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery
July 12, 2018 - N°20180193382

The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using cxc chemokines and the receptors to which they agonize. It has been found that certain chemokines, including cxcl4, cxcl9, cxcl10, and cxcl12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment ...
Nanocarriers and their processing for diagnostics and therapeutics
Rhode Island Hospital
July 12, 2018 - N°20180193344

The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis..
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of dek protein and related methods
The Regents Of The University Of Michigan
July 05, 2018 - N°20180187196

The present invention provides methods of treatment using inhibitors of dek protein and dek activity. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which dek has been implicated.
Compositions and methods related to multimodal therapeutic cell systems for autoimmune indications
Rubius Therapeutics, Inc.
July 05, 2018 - N°20180187155

The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease..
Bispecific antibodies that neutralize tnf-alpha and il-6: novel therapeutic agents for autoimmune disease
Ibc Pharmaceuticals, Inc.
July 05, 2018 - N°20180186898

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising ...
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services
July 05, 2018 - N°20180186888

Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel ...
Anti cd37 antibodies
Boehringer Ingelheim International Gmbh
July 05, 2018 - N°20180186876

Chimeric and humanized anti-cd37 antibodies and pharmaceutical compositions containing them are useful for the treatment of b cell malignancies and autoimmune and inflammatory diseases that involve b cells in their pathology.. .
Immunoglobulin constant region fc receptor binding agents
Gliknik Inc.
July 05, 2018 - N°20180186862

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function.
Cyclic di-nucleotides as modulators of sting
July 05, 2018 - N°20180186828

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious ...
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Heteroaryl substituted aminopyridine compounds
Bristol-myers Squibb Company
July 05, 2018 - N°20180186799

Disclosed are compounds of formula (i) or salts thereof, wherein het is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of formula (i) by a nitrogen ring atom in said heteroaryl and wherein ...
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]...
Arena Pharmaceuticals, Inc.
July 05, 2018 - N°20180186738

The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (compound 1) in the treatment of s1p1 receptor-associated disorders, for example, diseases ...
In vitro epithelial models comprising lamina propria-derived cells
Emulate, Inc.
July 05, 2018 - N°20180185844

An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells.
Human antibodies to pd-1
Regeneron Pharmaceuticals, Inc.
July 05, 2018 - N°20180185668

The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
City Of Hope
July 05, 2018 - N°20180185497

The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (odn) sequence conjugated to a short-activating rna (sarna) or an antisense oligonucleotide sequence (aso), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating cebpa, and method of reducing activity of ...
Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
Pin Pharma, Inc.
July 05, 2018 - N°20180185441

The present specification provides immunosuppressive tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease.. .
Compositions and methods for diagnosis and treatment of inflammation
The United States Of America As Represented By The Secretary Of The Navy
July 05, 2018 - N°20180185316

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, ...
Fcrn antagonists and methods of use
The Board Of Regents Of The University Of Texas System
June 28, 2018 - N°20180179258

Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
Loading